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IMPORTANCE OF STREAMLINING
DATA COLLECTION
The goal of the U.S. Food and Drug Administration (FDA)
guidance documents is to provide insight into the data nec-
essaryforFDAreviewerstoreliablyassesstherisk–benefit
ratio of an investigational agent for a particular clinical in-
dication. The current FDA registration guidance for cancer
therapy trials does not completely describe the level of de-
tailnecessaryforinformativedatacapturetosupportclaims
of safety and efficacy for supplemental indications of new
cancer treatments [1]. The guidance, as currently set out,
does not distinguish drugs with substantive safety informa-
tion and a definite benefit to patients from drugs with lim-
ited safety data that may carry safety risks that have not yet
beenrecognized.Datacollectionrequirementsthusbecome
essentially the same whether for a primary indication or a
supplemental application. This can result in collection of
excessive and sometimes unnecessary data by investiga-
tors,particularlyfortrialsdesignedtoexploreadditionalin-
dications where substantial toxicity data about an agent
already exist. Further, because there is no established stan-
dardforcollectionofdatainsupportofsupplementalappli-
cations, sponsors interpret the requirements variably,
resulting in inconsistent quality and quantity of data. Fre-
quently, the data collected do not result in modifications to
FDA labeling or inform medical practice, yet the data col-
lectionrequirementsaddcomplexityandcosttoconducting
the study. Therefore, optimized standards for data collec-
tion should be developed for well-studied cancer therapies
to improve the efficiency of safety evaluations without sac-
rificing the scientific integrity and validity of study results.
Streamlining data collection will help ensure better pa-
tientsafetybyimprovingtheoverallqualityofdatasubmit-
ted in supplemental applications. Collecting essential data
that will help inform patient safety, such as toxicities lead-
ing to death or dose discontinuations, is more important
thancollectinglargeamountsofdata,suchascatalogingall
mildadverseevents,thatultimatelyaddlittleinformationto
the existing safety profile of the drug. Collection of unused
data may actually distract from gleaning crucial informa-
tion. When faced with large amounts of safety data, it be-
comes difficult to prioritize safety events, distracting sites
from focusing on the collection of important information,
such as understanding what makes physicians or patients
modify or stop treatment. Thus, large amounts of data can
sometimesobfuscateknowledgeofnewandrelevantsafety
data. Furthermore, streamlining data collection will greatly
reducetheadministrativeburdenontheclinicaltrialsystem
and will focus finite resources on collecting key data ele-
ments. Reducing burdensome and unnecessary data collec-
tion will improve physician participation in clinical trials.
Surveys to understand why patients do not participate in
clinical trials reveal that doctors often do not recommend
clinical trials to their patients. Among various other rea-
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The Oncologist 2010;15:488–491 www.TheOncologist.comsons, doctors cite that they are weary of the high adminis-
trative workload and liability associated with conducting
clinical trials. In an effort to understand the burden of ex-
cessive data collection on trial administrators, a working
group,resultingasanoutgrowthofthe2008Conferenceon
ClinicalCancerResearchandformedundertheaegisofthe
American Society of Clinical Oncology (ASCO), solicited
input from several cooperative group and industry sites. Of
110 responses received to the poll, 85% expressed the
view that data optimization (as recommended below)
wouldmoderatelyorsignificantlyimpactsiteresources,al-
lowingcollectionofhigherqualitytargeteddataandgreater
participation in the clinical trials process [2].
POTENTIAL TRADEOFFS OF DATA OPTIMIZATION
In order to further explore the tradeoffs between complete
and optimal data collection, the Data Optimization Work-
ing Group assessed the extent of safety data collection nec-
essary and sufficient to inform clinical and regulatory
decisions in a supplemental application with the basic as-
sumptions that:
• Streamlined toxicity data collection will not be used for
initial indications (or the first supplemental application
following accelerated approval).
• Streamlined toxicity data collection will be used only if
the prior approval process included a safety database that
was acceptable for a full regulatory approval.
• The statistical analysis plan will be structured to mini-
mize the risk of missing important safety signals.
• Data on serious adverse events (SAEs), deaths, and dose
modificationsand/ordiscontinuations(withreasons)will
be collected for all patients on all study arms.
• Dataontargetedadverseevents(AEs)wouldbecollected
based on the known safety profile and pharmacology of
the drug and the study patient population.
Streamlining data collection will ensure that the data
collected will be used and that unnecessary data will not be
collected. Data collection requirements will vary as neces-
sary depending on whether a sufficiently large safety and
drug interaction profile already exists, the similarity of the
study population to the population for approved use, the
similarity of the supplemental regimen to the regimen al-
ready approved and, finally, whether the supplemental ap-
plication follows initial full or accelerated approval. By
collecting data on SAEs, deaths, dose modifications and/or
discontinuations,andtargetedAEsofinterestinallpatients
onallstudyarms,sponsorsarereasonablyaslikelytodetect
important safety signals as with the current data collection
process.
STUDY ORGANIZATION AND PARTICIPANTS
AttheConferenceonClinicalCancerResearchheldinSep-
tember 2008, a panel on Data Submission Standards and
EvidenceRequirementsproposedaframeworkfordatacol-
lection necessary to support claims of safety and efficacy
for supplemental new drug applications (NDAs) and bio-
logiclicenseapplications(BLAs)[3].Inordertofurtherex-
plore elements of that framework, ASCO formed the Data
Optimization Working Group. The Working Group pro-
vided a forum for all interested stakeholders (the FDA, the
National Cancer Institute [NCI], academia, industry, and
advocacy) to retrospectively review data sets from com-
pleted phase III trials, many that were used for FDA sup-
plemental approvals, and discuss potential revisions to data
collection standards.
Fourcompaniesandonecooperativegroupcollaborated
on this project. A statistical analysis plan was developed,
reviewed by the FDA, and used by all participating spon-
sors. The project involved a reanalysis of eight trials, in
both the metastatic and adjuvant settings, studying cyto-
toxic chemotherapy, targeted biological therapy, and hor-
monal therapy, as shown in Tables 1 and 2 [4].
STUDY FINDINGS AND RECOMMENDATIONS
The purpose of this study was to determine whether impor-
tantsafetyinformationwouldbelostbyonlygatheringtox-
icity data on a subsample of patients enrolled in a
supplemental NDA trial with a drug for which a substantial
toxicityprofilealreadyexists.Incandidatetrialswheresub-
sampling is appropriate, it is assumed that SAE informa-
tion, including all deaths, dose discontinuations, and dose
modifications along with the associated reasons, would
continuetobecollectedonallpatients.Thereanalysisdem-
onstrated that data subsampling did not appear to omit im-
portant information about the safety profile, that is, similar
conclusions regarding the safety profile would have been
reached if a subsampling approach had been used.
The study identified statistical methods for determining
appropriate subsampling sizes that can be scaled to fit dif-
ferent cutoff rates. The subsampling size range recommen-
dations using this statistical methodology are as follows.
For determining subsampling size (assuming a 2% ex-
cess and a two-arm trial):
• Inthemetastaticsetting,approximately400–500patients
should be subsampled (full study size, 800–1,200 pa-
tients).
• Intheadjuvantsetting,atotalsizeofapproximately400–
900 patients should be subsampled (full study size, 800–
6,000 patients).
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trials with 600 patients.
Thestudyalsoexaminedvarioussubsamplingmethods,
such as sampling patients at random, sampling study cen-
tersatrandom,samplingpatientsatthelargestcenters,sam-
pling the first patients enrolled, sampling the last patients
enrolled, and sampling the first and last patients enrolled
(the last patients enrolled and the first and last patients en-
rolled were analyzed only for comparative purposes, not as
a practical methodology). Sampling by centers at random
was determined to be the most logistically feasible and ac-
curate methodology for subsampling. To ensure full repre-
sentation, a stratified population of patients from small,
medium, and large centers should be chosen.
A lack of consensus regarding data collection, specifi-
cally toxicity data, has led to frequent discordance between
practices in NCI cooperative groups and industry-spon-
sored clinical trials. The goal of this project is to recom-
mend and justify sufficient data collection to generate
safety data for drug labeling and clinical use and to reduce
collection of unnecessary data elements in supplemental
NDAs and BLAs. The effort and resources saved can be
better channeled to focus on collecting more meaningful
and accurate information that informs clinical and regula-
tory decisions and leads to greater participation in the clin-
ical trial process.
FDA RESPONSE
Inaguidancepublishedin2001(CancerDrugandBiologic
Products—Clinical Data in Marketing Applications), the
FDA provided recommendations for sponsors on data col-
lection for cancer clinical trials submitted to the agency to
Table 1. Candidate trials evaluated in the study in the metastatic setting
Company, candidate study Patient population Treatment Trial size Primary endpoint
Genentech, AVF2107g First-line mCRC Arm 1, bolus IFL plus placebo;
arm 2, bolus IFL plus rhuMAb
VEGF; arm 3, 5-FU and LV
plus rhuMAb VEGF
813 OS
Genentech, ECOG 4599 First-line nonsquamous
NSCLC
Arm 1, paclitaxel and
carboplatin; arm 2, paclitaxel,
carboplatin, and bevacizumab
878 OS
Genentech, AVAIL First-line nonsquamous
NSCLC
Arm 1, cisplatin and
gemcitabine; arm 2, cisplatin,
gemcitabine, and bevacizumab
656 PFS
GSK, EGF 30001 Metastatic breast Arm 1, paclitaxel and placebo;
arm 2, paclitaxel and lapatinib
580 TTP
Eli Lilly and Co., JMDB First-line NSCLC Arm 1, cisplatin plus
pemetrexed; arm 2, cisplatin
plus gemcitabine
1,669 OS
Abbreviations: 5-FU, 5-fluorouracil; AVAIL, Avastin in Lung; bolus-IFL, irinotecan, 5-FU, and LV; ECOG, Eastern
Cooperative Oncology Group; JMDB, H3E-MC-JMDB; LV, leucovorin; mCRC, metastatic colorectal cancer; NSCLC,
non-small cell lung cancer; OS, overall survival; PFS, progression-free survival; rhuMAb VEGF, recombinant human
monoclonal antibody vascular endothelial growth factor; TTP, time to tumor progression.
Table 2. Candidate trials evaluated in the study in the adjuvant setting
Company, candidate
study Patient population Treatment Trial size
Primary
endpoint
Novartis, BIG 1–98 PMP women with HR
 EBC Arm 1, letrozole; arm 2, tamoxifen 8,028 DFS
CALGB, 89803 Patients with resected adenocarcinoma
of the colon
Arm 1, LV and 5-FU (500); arm 2,
irinotecan, LV (20 mg/m
2), and
5-FU
1,264 OS
Genentech, HERA HER-2
 adjuvant breast cancer Arm 1, observation; arm 2,
trastuzumab
3,386 DFS
Abbreviations: 5-FU, 5-fluorouracil; BIG, Breast International Group; CALGB, Cancer and Leukemia Group B; DFS,
disease-free survival; EBC, early breast cancer; HER, human epidermal growth factor receptor; HERA, Herceptin
Adjuvant; HR, hormone receptor; LV, leucovorin; OS, overall survival; PMP, postmenopausal.
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tal applications for new drug and biologic indications. The
regulations(21CFR314.50)requirethatsupportingdatabe
submitted with study reports from well-controlled trials,
but they do not describe the amount and type of data that
should be collected.
Commercial sponsors may collect large amounts of
information to ensure that they have all the data that reg-
ulatory agencies might request. Noncommercial organi-
zations, for example, U.S. cooperative groups, frequently
collect less information than commercial entities, although
their trials may provide adequate data for important risk–
benefit assessments supporting regulatory approvals. The
FDA recognizes that extensive data collection can be ex-
pensive and time-consuming and that collection of unnec-
essary data is not an optimal use of clinical trial resources.
In the 2001 guidance, the FDA acknowledged that it is
notpossibletoprovideprecisedatacollectionrequirements
that could be applied to all trials because of the complexity
and variability of clinical trial design. The FDA strongly
encouraged sponsors to develop specific proposals for data
collection and discuss their proposals with the agency prior
to initiating clinical trials. The FDA maintained that agree-
ment between the agency and the sponsor of the drug or bi-
ologic on prespecified data collection plans would “avoid
the collection of unnecessary information, allowing re-
sources to be directed toward studying important end-
points.”
Asdiscussedinthe2001guidance,thefollowingfactors
should be considered when assessing what data elements
are necessary to collect:
• The type of regulatory submission (e.g., new marketing
application versus efficacy supplement).
• The similarity of the proposed new use of the drug to al-
ready approved uses of drugs.
• The population being studied (e.g., patients in the surgi-
cal adjuvant setting, patients receiving first-line treat-
ments, or patients with refractory disease).
• The amount of available supplemental information from
other sources on the safety of the drug, such as data from
trials in a similar population.
The goal of the Data Submission Standards and Evi-
dence Requirements project (Panel 1) was to identify the
scopeofdatacollectionsufficienttogeneratesafetydatafor
drug labeling and clinical use and to reduce collection of
unnecessary data elements in supplemental NDAs and
BLAs.Astudywasconductedtodeterminewhetherimpor-
tant safety information would be omitted by collecting data
on a subsample of patients enrolled in trials to support sup-
plemental BLAs or NDAs for approved drugs with exten-
sive safety information already available. Data sampling
did not appear to omit safety information that would be
needed for labeling or the benefit–risk evaluation.
AlthoughthisstudyfocusedonsupplementalNDAsand
BLAs for cancer drugs, the FDA believes that these find-
ings could apply to safety data collection for supplemental
NDAs and BLAs for all therapeutic drug classes. Safety
data collection from all subjects would still be needed for
initial marketing claims for NDAs and BLAs. However,
based on the factors outlined in the guidance (i.e., type of
submission, similarity of proposed use to approved use,
population being studied, available additional information
for other sources), it should be possible to more narrowly
focus the scope of data collected without a detrimental im-
pact on the regulatory evaluation of supplemental market-
ing applications of drugs or biologics.
The FDA is committed to developing a guidance appli-
cable to all therapeutic classes. That guidance will further
clarify and illustrate the principles outlined in the 2001
guidance for cancer drugs and biologics, as well as incor-
porate the findings from the Data Submission Standards
and Evidence Requirements project.
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